A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced vision due to swelling in the macula, central part of the retina caused by a blocked vein in the retina (macula edema secondary to retinal vein occlusion)

You likely can't join if

• Concurrent disease that causes substantial decrease of BCVA, is expected to limit BCVA recovery or is likely to require medical or surgical intervention during the study in the study eye.
• Prior treatment of the study eye with any of the following drugs (any route of ophthalmic administration) or procedures: a. Anti-angiogenic drugs at any time including investigational therapy (e.g., with anti-angiopoietin/anti-VEGF bispecific monoclonal antibodies). b. Previous use topical steroids within 4 weeks (28 days) from the screening visit, or intraocular or periocular steroids within 16 weeks (112 days) from the screening visit, or steroid implants at any time. c. Previous treatment with intraocular or periocular implant, gene therapy, or cell therapy at any time. d. Treatment with ocriplasmin at any time. e. Vitreoretinal surgery (including scleral buckling) at any time. f. Any intraocular surgery, including cataract surgery, within 12 weeks (84 days) before the screening visit. g. Previous treatment with retinal laser photocoagulation.
• Prior treatment of the fellow eye with any of the following: a. Gene therapy, or cell therapy in the fellow eye at any time.
• Participation in other clinical studies requiring administration of investigational treatments (other than vitamins and minerals) at the time of screening visit, or within 30 days or 5 half-lives of administration of the previous study intervention, whichever is longer.
• Presence or history of the following ocular conditions: a. Advanced age-related macular degeneration (neovascular AMD or geographic atrophy) in the study eye. b. Diabetic macular edema or diabetic retinopathy, defined in diabetic participants as diabetic retinopathy lesions outside the area of the vein occlusion in the study eye and anywhere in the retina in the fellow eye. c. Anterior segment neovascularization, vitreous hemorrhage, retinal detachment in the study eye. d. Vitreomacular traction, epiretinal membrane or structural damage to the macula that is considered by the Investigator to significantly affect central vision or preclude improvement in vision in the study eye. e. Macular hole of stage 2 and above in the study eye. f. Myopia of a spherical equivalent of at least 8 diopters prior to any refractive or cataract surgery in the study eye. g. Corneal transplant or corneal dystrophy in the study eye. h. Idiopathic or autoimmune uveitis in the study or in the fellow eye."
• Presence of the following ocular conditions at screening or baseline visit: a. Significant media opacities, including cataract, that interfere with BCVA, or imaging assessments (e.g., fundus photography [FP], optical coherence tomography (OCT)) in the study eye. b. Aphakia, or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium-aluminum-garnet [YAG] posterior capsulotomy performed more than 30 days before the screening visit), in the study eye. c. Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication); or history or likely future need of glaucoma surgery in the study eye. d. Intraocular inflammation/infection (including trace, or above, cells in the anterior chamber and/or vitreous) within 12 weeks (84 days) of the screening visit in the study or in the fellow eye. e. Extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in the study or in the fellow eye.